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Background: Cardiovascular disease is more common in patients with chronic kidney 
  disease (CKD) than in the general population. Endothelial dysfunction is an early predictor of 
cardiovascular events.
Objective: We conducted a cross-sectional study in CKD patients to explore the association 
of metabolic syndrome (MetS) components with endothelial cell function.
Methods: We evaluated clinical and laboratory data in 161 CKD patients from stage 1 to stage 5. 
Endothelial function was estimated by flow-mediated dilatation (FMD) of the brachial artery 
and expressed as percentage change relative to baseline diameter. MetS was defined according 
to the National Cholesterol Education Program-Adult Treatment Panel III criteria.
Results: Patients were grouped into two groups according to whether or not they had MetS. 
FMD was significantly lower in the MetS group than in the group without MetS (P = 0.012). 
In a Pearson’s correlation analysis, FMD was significantly negatively correlated with waist 
circumference in women (r = –0.223, P = 0.03) and fasting blood glucose (r = –0.186, P = 0.001). 
Multiple linear regression analysis showed that fasting blood glucose was an independently 
associated factor for FMD.
Conclusion: MetS and some components of MetS (waist circumference in women and fasting 
blood glucose) are closely associated with a decreased FMD in CKD patients.
Keywords: metabolic syndrome, endothelial dysfunction, flow-mediated dilatation, chronic 
kidney disease
Introduction
Metabolic syndrome (MetS) is a cluster of metabolic abnormalities, including visceral 
obesity, high blood pressure, hyperglycemia, and dyslipidemia,1–4 which are   associated 
with increased cardiovascular risk in various clinical conditions.5,6 The   mechanisms 
through which this syndrome increases cardiovascular risk are only partially 
  understood. Recently, research has found that several of the individual components 
of MetS, including high blood pressure,7 hyperglycemia,8 and abdominal obesity,9,10 
have been related to increased endothelial dysfunction in the general population.
Endothelial dysfunction, detected noninvasively as a decreased flow-mediated dila-
tion (FMD) of the brachial artery,11,12 is an early and potentially reversible functional 
disturbance in the development of vascular lesion and disease.13 It is also common in 
subjects with MetS, and it is believed to reflect the metabolic derangements present 
in this condition.14
In CKD, endothelial dysfunction also appears to predict cardiovascular disease 
(CVD) and outcome.15 Johnson et al16 have shown that MetS is exceedingly common 
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in CKD, and it is thus also a plausible cause of high morbidity 
and mortality. To date, the relationship of MetS to endothelial 
dysfunction has been evaluated mostly in the general popula-
tion but is not clearly elucidated in the CKD population. In 
the present study, we aimed to investigate the possible link 
of metabolic components of MetS of patients with CKD with 
endothelial function assessed by FMD.
Subjects and methods
Subjects and collection of data
This study was approved by the Ethics Committee of Peking 
University Third Hospital, Beijing, People’s Republic of 
China, and all patients gave written informed consent to all 
the procedures.
All patients visiting our CKD outpatient clinics from 
December 1, 2008 to June 30, 2010 were eligible to participate 
in this study except for those with (1) clinical or labora-
tory evidence of heart failure (New York Heart Association 
classes III–IV); (2) peripheral arterial disease; (3) pre-
existent chronic inflammatory disease; (4) cancer; (5) active 
arteriovenous fistula, which may interfere with the results of 
FMD; and (6) primary or secondary nephrotic syndrome. 
A total of 161 individuals (78 men and 83 women; age range 
20–88 years; mean 65.58 ± 14.57 years) were studied. All 
patients’ clinical data and laboratory test data were collected. 
A dedicated physician and nurse were responsible for all 
blood pressure, weight, and waist circumference measure-
ments and performed measurements under strict instructions 
  without any knowledge of the study protocol or objectives. 
The waist circumference measurement point in this study 
was the umbilical level. The mercury sphygmomanometer was 
calibrated regularly. The patients were allowed to take regular 
antihypertensive medications before each visit. The antihy-
pertensive medications prescribed during the previous days 
were recorded in detail to calculate the defined daily dose.17 
Moreover, every drug agent, such as angiotensin-converting 
enzyme inhibitors (ACEIs) and angiotensin receptor block-
ers (ARBs), β- or α-receptor blockers, calcium antagonists, 
statins, or aspirin, was recorded. Pre-existing CVD was 
evaluated. CVD in our study included coronary artery disease 
(angina pectoris and myocardial infarction), arrhythmia, con-
gestive heart failure, and cerebrovascular disease.
Glomerular filtration rate was estimated (eGFR) by the 
si  mplified Modified Diet in Renal Disease (MDRD) formula.
MetS definition
MetS was defined according to the National Cholesterol 
E  ducation Program-Adult Treatment Panel III18–20 when 
patients had at least three of the following five cr  iteria: 
(1) waist circumference .90 cm or 80 cm for men and 
women, respectively; (2) systolic blood pressure .130 mmHg 
and/or diastolic blood pressure .85 mmHg; (3) serum trig-
lyceride (TG) levels .1.69 mmol/L (150 mg/dL); (4) serum 
high-density lipoprotein (HDL) cholesterol ,1.04 mmol/L 
(40 mg/dL) in men and ,1.30 mmol/L (50 mg/dL) in 
women; and (5) fasting plasma glucose .5.6 mmol/L 
(100 mg/dL).
Laboratory methods
Blood samples were obtained in the early morning after 
the subjects had fasted for at least 8 hours. Biochemical 
indices, such as fasting glucose, total cholesterol, TG, HDL 
cholestrol, low-density lipotrotein (LDL) cholesterol, blood 
urea nitrogen, serum creatinine, calcium, and phosphate, 
were determined using standard methods with the Olympus 
AU5400 chemistry immunoanalyzer (Olympus, Tokyo, 
Japan). 
Flow-mediated dilatation
Noninvasive endothelium-dependent FMD was measured 
in each subject after they took a 10-minute rest in a supine 
position with an empty abdomen. The right brachial artery 
image was recorded in a longitudinal section 15 cm above 
the antecubital fossa using a 7 MHz linear array trans-
ducer and a standard Acuson 128XP/10 system (Siemens, 
Erlangen, G  ermany). Baseline brachial artery diameter 
was measured using an automated wall tracking system 
(Sonoline G50, Siemens), which utilizes movement in the 
radiofrequency amplitude peaks over the cardiac cycle to 
identify the arterial walls.11,21 A pneumatic cuff was then 
inflated to 50 mmHg above systolic blood pressure on the 
forearm for 5 minutes to induce a reactive hyperemia. Cuff 
de  flation resulted in increased flow through the brachial 
artery, stimulating endothelial-dependent dilatation. The 
percentage of the change in brachial artery diameter 1 min-
ute after cuff release to baseline diameter was recorded as 
FMD. Our coefficient of variation of FMD measurement in 
our study was 1.1% ± 0.2% intra-assay and 4.5% ± 1.0% 
interassay.
Statistical analysis
Statistical analysis was performed using SPSS software (v 16.0; 
SPSS Inc, Chicago, IL). Continuous variables are expressed 
as means ± standard deviation, and categorical variables are 
expressed as percentages. Independent sample Student’s t-test or 
one-way analysis of variance were used to compare two groups 
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or multiple groups of normally di  stributed continuous variables, 
and the Mann–Whitney U test was used for non-normally 
distributed variables. For comparison of categorical variables 
in two groups, such as the proportion of gender distribution, 
the χ2 test was employed. Pearson’s correlation analysis was 
performed to explore the possible relationship between FMD 
and other continuous variables (Spearman’s correlation analysis 
was performed if they were abnormal distributed variables). 
Multiple linear regression analysis was performed among those 
significant variables in Pearson’s correlation analysis. A value 
of P , 0.05 was taken as statistically significant.
Results
Patients’ clinical characteristics
Demographic data of the study population are listed in 
Table 1. Of the 161 patients, 78 were male and 83 were 
female. Mean age was 65.58 ± 14.57 years. The etiologies 
of CKD were glomerulonephritis (29.2%), diabetes mellitus 
(13.7%), hypertension (20.5%), and others (21.7%).
Comparison of clinical and laboratory 
data of patients with and without MetS
Thirty-seven percent of the patients displayed MetS   according to 
the National Cholesterol Education Program-Adult   Treatment 
Panel III. As there was no significant difference in MetS and 
non-MetS between male and female patients, patients were 
grouped into two groups according to whether or not they had 
MetS. As is shown in Table 2, patients in the first group (those 
with MetS) had an expected higher weight and waist circumfer-
ence than patients in the second group (both P = 0.000). Also, 
primary renal diagnosis of diabetic nephropathy was more 
frequent (P = 0.008), TG (P = 0.000) and glucose (P = 0.000) 
were higher, and HDL cholesterol (P = 0.001) differed among 
the two groups, being lower in the MetS group compared with 
in the non-MetS group. There were no significant differences 
between the two groups with regard to blood pressure, MDRD 
stage, total cholesterol, calcium, phosphate, LDL, blood urea 
nitrogen, and serum creatinine. Notably, FMD was significantly 
lower in the group of patients with MetS than in the group 
without MetS (7.65% ± 3.93% vs 9.99% ± 5.54%, z = −2.46, 
P = 0.014.). We found a higher total defined daily dose of anti-
hypertensive medication in patients with MetS than in patients 
without MetS, but without significant difference.
Association between FMD and other 
variables
Pearson’s correlation analysis between FMD and other vari-
ables is shown in Table 3. A significant negative correlation 
was found between FMD and waist circumference in women 
(r = −0.223, P = 0.03) but not in men (r = −0.055, P = 0.625); 
moreover, FMD was inversely associated with fasting glu-
cose (r = −0.254, P = 0.001) (Table 3) and 24-hour urine 
protein excretion (Spearman correlation analysis r = −0.204, 
P = 0.011), and FMD was also weakly correlated with serum 
calcium. FMD was higher in nondiabetic patients than in 
diabetic CKD patients (10.07% ± 5.48% vs 7.12% ± 3.60%, 
P = 0.000) and was also higher (10.07% ± 5.48% vs 
6.97% ± 3.95%, P = 0.009) in nondiabetic patients than 
in high-fasting glucose patients without diabetes (fasting 
glucose .6.1 mmol/L but ,7.0 mmol/L), but there was 
no significant difference in FMD between diabetic and 
high-fasting glucose patients. There was no significant dif-
ference in patients’ FMD between those with pre-existing 
CVD and those without CVD. No correlation was observed 
between FMD and age, blood pressure, serum cholesterol, 
TG, phosphate, uric acid, HDL cholesterol, LDL cholesterol, 
serum creatinine, and blood urea nitrogen (Table 3). We did 
not find an effect of drug agents such as ACEIs/ARBs, 
Table1 Demographic characteristics of the study population
N ± SD or number 
and percentage
Patients (number) 161
Male/female (ratio) 78/83
Age (mean ± SD), years 65.58 ± 14.57
Weight (mean ± SD), kg 65.56 ± 11.99
Waist circumference (mean ± SD), cm 82.44 ± 11.90
Primary diagnosis (%)
  Chronic glomerulonephritis 29.2
  Diabetes mellitus 13.7
  interstitial nephritis 14.9
  Hypertension 20.5
  Others 21.7
Systolic BP (mean ± SD), mmHg 117.75 ± 22.83
Diastolic BP (mean ± SD), mmHg 70.36 ± 14.17
  MDRD stage, %
  CKD stage i 1.9
  CKD stage ii 11.8
  CKD stage iii 47.8
  CKD stage iV 28.0
  CKD stage V 10.6
Pre-existing cardiovascular disease (%) 14
Total DDD of antihypertensive drug 1.45 ± 1.22
  ACEi DDD 0.27 ± 0.71
  ARB DDD 0.32 ± 0.57
  Calcium antagonist DDD 0.56 ± 0.74
 β -receptor blocker 0.08 ± 0.185
 Α -receptor blocker 0.05 ± 0.149
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin 
receptor blocker; BP, blood pressure; CKD, chronic kidney disease; DDD, defined 
daily dose; MDRD, Modified Diet in Renal Disease; SD, standard deviation.
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β- or α-blockers, Ca antagonists, statins, or aspirin on FMD 
  determination (data not shown).
Multiple linear regression analysis
Multiple linear regression analysis showed that only fasting 
blood glucose was an independently associated factor for 
FMD (Table 4).
Discussion
More than half of the mortality for CKD patients is attrib-
utable to CVD. The true impact of CVD on outcomes for 
dialysis patients is better illustrated by the rate of death 
from CVD, which is 10–20 times higher than in the general 
  population.22 Epidemiologic studies have shown an increased 
risk of cardiovascular mortality in the general population with 
MetS.23,24 The MetS is thought to be an important contributor 
to CVD among these patients and has become a major public 
health challenge around the world.25,26 How MetS increases 
Table 2 Clinical and laboratory data of patients with and without metabolic syndrome
Metabolic syndrome (n = 59) No metabolic syndrome (n = 102) P value
Age, years 66.34 ± 15.08 61.99 ± 15.20 0.068
Male/female 26/33 52/50 0.398
Weight (kg) 72.41 ± 11.30 61.60 ± 10.54 0.000
Waist circumference (cm) 91.01 ± 8.34 77.48 ± 10.58 0.000
Systolic BP (mmHg) 117.54 ± 24.41 117.87 ± 21.99 0.907
Diastolic BP (mmHg) 71.02 ± 15.36 69.98 ± 13.50 0.694
Primary diagnosis (n) (%)
  Chronic glomerulonephritis 14 (23.7) 33 (32.4) 0.283
  Diabetes mellitus 14 (23.7) 8 (7.8) 0.008
  interstitial nephritis 10 (16.9) 14 (13.7) 0.648
Hypertension 13 (22.0) 20 (19.6) 0.840
  MDRD stage (n) (%)
  CKD stage i 0 (0) 3 (2.9) 0.299
  CKD stage ii 7 (11.9) 12 (11.8) 1.000
  CKD stage iii 30 (50.8) 47 (46.1) 0.624
  CKD stage iV 18 (30.5) 27 (26.5) 0.590
  CKD stage V 4 (6.8) 13 (12.7) 0.294
Total cholesterol (mmol/L) 5.43 ± 1.47 5.14 ± 1.13 0.132
Triglycerides (mmol/L) 2.96 ± 1.95 1.66 ± 0.84 0.000
Calcium (mmol/L) 2.26 ± 0.11 2.25 ± 0.22 0.652
Phosphate (mmol/L) 1.29 ± 0.28 1.34 ± 0.24 0.232
HDL cholesterol (mmol/L) 1.32 ± 0.80 1.43 ± 0.40 0.001
LDL cholesterol (mmol/L) 3.29 ± 1.13 3.04 ± 0.96 0.350
Fasting glucose (mmol/L) 6.34 ± 1.58 5.50 ± 1.13 0.000
Uric acid (μmol/L) 412.99 ± 116.09 349.91 ± 112.81 0.334
Serum creatinine (μmol/L) 175.32 ± 70.82 200.56 ± 124.49 0.987
Blood urea nitrogen (mmol/L) 10.24 ± 3.61 11.78 ± 6.66 0.593
24-hour urine proteinuria excretion (g/day) 1.24 ± 1.84 0.94 ± 1.20 0.393
Pre-existing cardiovascular disease (%) 16.7 11.0 0.404
Total DDD of antihypertensive drug 1.78 ± 1.36 1.25 ± 1.1 0.969
FMD (%) 7.65 ± 3.93 9.99 ± 5.54 0.012
Abbreviations: BP, blood pressure; CKD, chronic kidney disease; DDD, defined daily dose; FMD, flow-mediated dilatation; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; MDRD, Modified Diet in Renal Disease.
Table 3 Correlation analysis between flow-mediated dilatation 
and other variables
Variables Correlation coefficient P value
Age −0.086 0.227
Systolic BP 0.005 0.953
Diastolic BP 0.058 0.469
UA 0.033 0.674
24-hour urine protein excretion −0.204 0.011*
Cr 0.124 0.177
BUN 0.118 0.137
egFR −0.002 0.984
Fasting glucose −0.254 0.001*
Triglycerides −0.105 0.186
Total cholesterol 0.030 0.708
HDL-C −0.041 0.602
LDL-C 0.061 0.441
Calcium 0.173 0.049*
Phosphate 0.042 0.594
Note: *Significant at P , 0.05. 
Abbreviations: BP, blood pressure; BUN, blood urea nitrogen; Cr, creatinine; 
eGFR,  estimated  glomerular  filtration  rate;  HDL-C,  high-density  lipoprotein 
cholesterol; LDL-C, low-density lipoprotein cholesterol; UA, uric acid.
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the risk of CVD is not completely understood. Previous 
studies suggest that abnormal metabolism, associated with 
end-stage renal disease per se or with a pre-existing MetS, 
could also be an important driver of endothelial dysfunction 
and CVD.
Many previous studies had shown that FMD may reflect 
endothelial function. Endothelial dysfunction is both an early 
marker of vascular disease and a facilitative process in the 
development of atherosclerosis in the general population 
and patients with CKD. The Northern Manhattan Study 
(NOMAS)27 has shown that hazard ratios for cardiovascular 
events were 43% greater in those with MetS and 24% greater 
in those with endothelial dysfunction than in those with nei-
ther, respectively, but there was no significant difference in 
patients’ FMD whether or not they had pre-existing CVD in 
our current study. It might be because the role of pre-existing 
CVD in endothelial dysfunction of CKD patients was less 
than with MetS or its components.
All the components of MetS can individually impair 
endothelial function. Several studies have shown that 
both hypertension28 and diabetes type 2 are associated 
with endothelial dysfunction in the general population.29 
  Experimental glucose loading also impairs endothelial 
function,30 and abdominal obesity is associated with 
  endothelial dysfunction.31 Impaired endothelial function was 
also reported in patients with low levels of HDL cholesterol.32 
Reduced endothelium-dependent vasodilation (EDV) was 
also reported in patients with elevated TG levels.33
Regarding the contribution of each MetS component in 
the pathogenesis of endothelial dysfunction in patients with 
MetS, a large study (n = 1016) by Lind reported that TG 
levels, waist circumference, and diastolic BP independently 
predicted EDV .34 Waist circumference was more strongly 
related to endothelial dysfunction followed by TG levels and 
diastolic blood pressure.34 In other reports, only HDL cho-
lesterol levels35 were independently associated with reduced 
FMD in patients with MetS.
In our study, FMD was significantly lower in the group 
of patients with MetS than in the group of patients with-
out MetS, indicating that MetS might be associated with 
endothelial dysfunction in patients with CKD. Moreover, 
patients with components of MetS, such as hyperglycemia 
(higher fasting blood glucose) and abdominal obesity in 
female CKD patients, correlated negatively with FMD, 
whereas other components, such as blood pressure, HDL 
cholesterol, and TG levels, did not correlate with FMD. 
Fasting blood glucose level was the only independently 
associated factor with endothelial dysfunction, but only 
13.7% of patients in our study were diabetic. The most 
common cause of CKD in China is glomerulonephritis, and 
many diabetic patients were followed up by an endocrine 
doctor. Only those patients with severe renal dysfunction 
were referred to a nephrologist.
We did not find the effect of blood pressure on FMD 
in our current study. This might have resulted from the 
patients’ blood pressure being controlled (mean systolic 
blood pressure was 117.75 ± 22 mmHg), and most of 
them received ACEIs/ARBs or calcium antagonist com-
binations with ACEIs/ARBs, so it is difficult to judge the 
effect of the antihypertensive drug category on endothelial 
dysfunction.
Some reports showed that serum uric acid levels are 
raised in MetS.36 Elevated serum uric acid levels appear to 
be associated with endothelial dysfunction and may play a 
role in the increased vascular risk of patients with MetS in 
the general population.36 In contrast to these results, we did 
not find that serum uric acid levels were associated with 
FMD, neither did we find that serum uric acid levels were 
significantly raised in CKD patients with MetS compared 
with those without MetS.
Our results did not show that there was any difference in 
patients with a different number of MetS components (data 
not shown).
Our results showed that FMD had no relationship with 
eGFR, indicating that endothelial dysfunction exists in 
early CKD stages, which may be a marker predicting CVD 
events in later stages of CKD. On the other hand, the eGFR 
by MDRD formula is not precisely for all stages of CKD. 
As previous reported,37 we also found that proteinuria was 
inversely associated with FMD.
Table 4 Coefficients of multiple regression analysis (dependent variable flow-mediated dilatation [%])
Unstandardized 
coefficients
SE Standardized 
coefficients
t P value 95% CI
Constant 11.56 1.29 8.95 0.000 9.01 to 14.11
Fasting glucose 
Waist circumstance 
Serum calcium
–0.44 
–0.10 
–0.03
0.20 −0.18 −2.17 
−1.17 
−0.33
0.03 
0.24 
0.74
–0.8 to –0.04 
Abbreviations: CI, confidence interval; SE, standard error.
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A few limitations remain in our study. The cross-sectional 
character of the present study cannot provide proof of direct 
causality between MetS components and FMD. Currently, we 
are performing a prospective, controlled, interventional study 
to explore the impact of management of the components of 
MetS (such as weight loss, control of blood glucose) on FMD 
in patients with CKD.
In summary, we showed that MetS and some components 
of MetS (fasting blood glucose and waist circumference 
in women) are closely associated with decreased FMD in 
CKD patients.
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